GENETICS, BIOMARKERS, AND NEUROPATHOLOGY (GBN) CORE: ABSTRACT The goal of the GBN Core is to support the efforts of PANUC to understand and treat cognitive impairment (CI) in Parkinson's disease (PD) and models of PD through human and animal studies. GBN provides logistical and analytical support to all four Projects and the Clinical Resource Core of PANUC as well as to linked U01 NS082137, one of ten projects funded by the NIH Parkinson's Disease Biomarker Program (PI: Dr. Zhang, also co-Leader of GBN Core). We will accomplish our goal through the following Specific Aims:
Specific Aim 1. GENETICS: Genotype new Clinical Resource Core participants for entry into Project 3 and Project 4, and validate putative genetic risk factors for CI in the PD Cognitive Genetics Consortium.
Specific Aim 2. CSF BIOMARKERS: Provide analysis of well established biomarkers for PD and Alzheimer's disease using CSF assays routinely performed in the GBN Core.
Specific Aim 3. NEUROPATHOLOGY: Provide expert analysis of tissue samples from Projects and Cores.
Specific Aim 4. DATA MANAGEMENT and STATISTICS: Provide expert data management and statistical support for the Clinical Resource Core and all Projects and analyze the high dimensional data collected in this Core. The GBN Core serves several initiatives in the NIH Blueprint. It uses existing NIH resources, contributes essential materials to NIH repositories, and is highly patient- oriented and translational.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS062684-06
Application #
8881525
Study Section
Special Emphasis Panel (ZNS1-SRB-J (07))
Project Start
2008-07-01
Project End
2015-07-31
Budget Start
2014-09-30
Budget End
2015-07-31
Support Year
6
Fiscal Year
2014
Total Cost
$418,116
Indirect Cost
$87,639
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Smulders, Katrijn; Dale, Marian L; Carlson-Kuhta, Patricia et al. (2016) Pharmacological treatment in Parkinson's disease: Effects on gait. Parkinsonism Relat Disord 31:3-13
Wang, Liyong; Maldonado, Lizmarie; Beecham, Gary W et al. (2016) DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. Neurol Genet 2:e72
Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2016) GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 31:95-102
Mata, Ignacio F; Davis, Marie Y; Lopez, Alexis N et al. (2016) The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot. Am J Med Genet B Neuropsychiatr Genet 171:925-30
Costa-Mallen, Paola; Zabetian, Cyrus P; Hu, Shu-Ching et al. (2016) Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease. J Neural Transm (Vienna) 123:1319-1330
Moelter, Stephen T; Weintraub, Daniel; Mace, Lauren et al. (2016) Research consent capacity varies with executive function and memory in Parkinson's disease. Mov Disord 31:414-7
Cholerton, Brenna; Larson, Eric B; Quinn, Joseph F et al. (2016) Precision Medicine: Clarity for the Complexity of Dementia. Am J Pathol 186:500-6
Davis, Marie Y; Johnson, Catherine O; Leverenz, James B et al. (2016) Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol 73:1217-1224
Costa-Mallen, Paola; Zabetian, Cyrus P; Agarwal, Pinky et al. (2016) Response to the letter ""Haptoglobin phenotype and Parkinson disease risk"" by Delanghe et al. Parkinsonism Relat Disord 22:110-1
Crane, Paul K; Gibbons, Laura E; Dams-O'Connor, Kristen et al. (2016) Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. JAMA Neurol 73:1062-9

Showing the most recent 10 out of 151 publications